title: The 5 stages of biotechnology management.
abstract: The biologics pipeline is flush with new technologies, many of which will come with high prices and treat more prevalent conditions. Payers will feel mounting pressure to manage costs effectively. To do this, more sophisticated economic models sensitive to unique and complex mechanisms of action are needed.
authors: Thomas
authors: T
authors: Baker
references: JAMA. 2004 May 19;291(19):2344-50
references: 15150206
references: Am J Manag Care. 2003 Sep;9(4 Suppl):S87-98
references: 14527109
references: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references: 15329413
references: Biotechnol Healthc. 2004 May;1(2):46-51
references: 23372499
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Clin Immunol Immunopathol. 1997 Sep;84(3):223-43
references: 9281381
references: Biotechnol Healthc. 2004 Sep;1(4):37-44
references: 23397380
references: Biotechnol Healthc. 2004 Jul;1(3):31-40
references: 23397364
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: Clin Ther. 2004 Aug;26(8):1341-54
references: 15476915